Search
Aluminum hydroxide
go.drugbank.com/drugs/DB06723ApprovedInvestigationalAluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. … Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
Mixtures: Diovol EX Tab, DICLOFENACO SÓDICO 100 MG - HIDROXIDO DE ALUMINIO GEL EQUIVALENTE A200 MGProducts: ALU-TAB TABLET 600 MG, ACTAL TABLET 216 mgSecnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigationalIt is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class … [A245503] Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades.
Mixtures: ITRACONAZOL 33.3 MG + SECNIDAZOL 166.66 MG CÁPSULA, FLUCONAZOL+SECNIDAZOL 75MG/1000 MGProducts: BIANOS 500 MG, SEDIL500 MGAlmonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.
Synonyms: 2-Propenamide, N-[5-[[4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-, N-[5-[[4-(1-Cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-2-propenamideOrdesekimab
go.drugbank.com/drugs/DB16649InvestigationalOrdesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.
Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamideProducts: ROZLYTREK 200 MG SERT KAPSÜL, 90 ADET, ROZLYTREK 100 MG SERT KAPSÜL , 30 ADETGelatin
go.drugbank.com/drugs/DB11242ApprovedInvestigationalVet approvedWithdrawn[A32432] Interestingly, horse gelatin has been studied and it was found that in the horse, gelatin influences the homeostasis of the amino acids required for cartilage synthesis [A32434]. … Gelatin is a multifunctional ingredient that is used in foods, pharmaceuticals, cosmetics, and photographic films as a gelling agent, stabilizer, thickener, emulsifier, as well as film former.
Mixtures: Gelofusin Iso 40 mg/ml Infusionslösung, GELOFUSINE IN 500ML PLASTIC CONTAINERVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalIt was first described in 1998 at the Pierre Fabre research center in France. … In 2009, vinflunine was approved by the European Medicines Agency (EMA) as a second-line therapy of metastatic and advanced urothelial cancer after failure of platinum-based treatment [A32626].
Products: Javlor Concentrate for Solution for Infusion 25 mg/mLSufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalIt is administered by the intravenous, epidural and sublingual routes. … Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.
Synonyms: N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilideFenobam
go.drugbank.com/drugs/DB12931InvestigationalFenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance
Axatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigational[A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … [L51194,L51199] It is the first FDA-approved anti-CSF-1R antibody directed against inflammatory and fibrotic drivers in chronic graft-versus-host disease.[L51199]